Opin vísindi

Browsing by Author "Maggadóttir, Sólrún Melkorka"

Browsing by Author "Maggadóttir, Sólrún Melkorka"

Sort by: Order: Results:

  • Icon
    A phase I/II escalation trial design T-RAD : Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT) 
    Maggadóttir, Sólrún Melkorka; Kvalheim, Gunnar; Wernhoff, Patrik; Sæbøe-Larssen, Stein; Revheim, Mona Elisabeth; Josefsen, Dag; Wälchli, Sébastien; Helland, Åslaug; Inderberg, Else Marit (2022-11-10)
    Background: Adoptive cellular therapy (ACT) with genetically modified T cells aims to redirect T cells against resistant cancers through introduction of a T cell receptor (TCR). The Radium-4 TCR was isolated from a responding patient in a cancer ...
  • Icon
    Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy 
    Dillard, Pierre; Köksal, Hakan; Maggadóttir, Sólrún Melkorka; Winge-Main, Anna; Pollmann, Sylvie; Menard, Mathilde; Myhre, Marit Renée; Mælandsmo, Gunhild M.; Flørenes, Vivi Ann; Gaudernack, Gustav; Kvalheim, Gunnar; Wälchli, Sébastien; Inderberg, Else Marit (2021-03-03)
    T cell receptor (TCR)-engineered T cell therapy is a promising cancer treatment approach. Human telomerase reverse transcriptase (hTERT) is overexpressed in the majority of tumors and a potential target for adoptive cell therapy. We isolated a novel ...
  • Icon
    Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer 
    Maggadóttir, Sólrún Melkorka; Dueland, Svein; Mensali, Nadia; Hamre, Hanne; Andresen, Per Arne; Myhre, Marit Renée; Juul, Hedvig V.; Bigalke, Iris; Lundby, Marianne; Hønnåshagen, Turid Kirsti; Sæbøe-Larssen, Stein; Josefsen, Dag; Hagtvedt, Trond; Wälchli, Sébastien; Kvalheim, Gunnar; Inderberg, Else Marit (2024-06-05)
    We previously demonstrated the antitumor effectiveness of transiently T cell receptor (TCR)-redirected T cells recognizing a frameshift mutation in transforming growth factor beta receptor 2. We here describe a clinical protocol using mRNA TCR-modified ...